Results 361 to 370 of about 281,573 (395)

Treatment of Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2020
Chronic Lymphocytic Leukemia Treatment of CLL, the most common leukemia in the West, has undergone a revolution in the past few years with the development of agents that target signaling kinases an...
J. Burger
semanticscholar   +1 more source

Chemoimmunotherapy of chronic lymphocytic leukemia

Nature Reviews Clinical Oncology, 2007
The past two decades have seen a major paradigm shift in the therapy of chronic lymphocytic leukemia (CLL), with the treatment goal shifting from symptom palliation to the attainment of maximal disease control using the most effective frontline regimens available, thus prolonging survival and possibly leading to cure.
Michael J. Keating, Constantine S. Tam
openaire   +5 more sources

Transplantation in chronic lymphocytic leukemia

Current Hematologic Malignancy Reports, 2007
Although there have been no randomized trials comparing the outcome of stem cell transplantation (SCT) with standard chemotherapy for patients with chronic lymphocytic leukemia (CLL), increasingly, both autologous and allogeneic SCT approaches are being explored in this disease.
John G. Gribben, Rifca Le Dieu
openaire   +3 more sources

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Journal of Clinical Oncology, 2018
Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based on ...
S. Stilgenbauer, B. Eichhorst, J. Schetelig, P. Hillmen, J. Seymour, S. Coutre, W. Jurczak, S. Mulligan, A. Schuh, S. Assouline, C. Wendtner, A. Roberts, M. Davids, J. Bloehdorn, T. Munir, S. Böttcher, Lang Zhou, A. Salem, Monali Desai, B. Chyla, Jennifer Arzt, S. Y. Kim, M. Verdugo, G. Gordon, M. Hallek, W. Wierda   +25 more
semanticscholar   +1 more source

Immunophenotyping of Chronic Lymphocytic Leukemia

Clinical Laboratory, 2017
Chronic Lymphocytic Leukemia (CLL) is one of the most common diagnoses made by flow cytometry laboratories. There is no consensus on which markers need to be used in flow cytometry for accurate immunophenotyping. Herein, we investigated the role of markers used in flow cytometry in the distinction between CLL and MCL.A total 339 recently diagnosed B ...
Falay, Mesude, Ozet, GÜLSÜM
openaire   +4 more sources

[Chronic lymphocytic leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2014
Currently, several novel drugs are available for chronic lymphocytic leukemia (CLL) in Western countries. Of these drugs, those that inhibit the B-cell receptor (BCR) signaling pathway are the most promising. Ibrutinib inhibits BTK in the BCR pathway and can be administered orally. The results of several clinical trials suggest that ibrutinib is highly
openaire   +3 more sources

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Blood, 1999
R. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. L. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, S. Lichtman, P. Schulman, V. Vinciguerra, K. Rai, M. Ferrarini, N. Chiorazzi   +15 more
semanticscholar   +1 more source

Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2005
Manlio Ferrarini, Nicholas Chiorazzi, Kanti R. Rai   +2 more
openaire   +3 more sources

Chronic Lymphocytic Leukemia

The American Journal of the Medical Sciences, 1994
Ronald P. McCaffrey, Priscilla B. Caguioa, Sualp Tansan   +2 more
openaire   +3 more sources

Chronic Lymphocytic Leukemia

Orvosi Hetilap, 2008
Béla Kajtár, Hajna Losonczy
openaire   +5 more sources